FDA-2025-N-0873 for “Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments.” Entrance for the public meeting participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for fiscal years (FYs) 2028 to 2032. Participating in the Public MeetingRegistration: Information about how to register for the public meeting is available on FDA's web page for this public meeting: https://www.fda.gov/​industry/​generic-drug-user-fee-amendments/​gdufa-iv-fiscal-years-2028-2032. Streaming Webcast of the Public Meeting: When available, the virtual link to the hybrid public meeting will be posted on FDA's public web page at https://www.fda.gov/​industry/​generic-drug-user-fee-amendments/​gdufa-iv-fiscal-years-2028-2032.